首页工具

登录

搜索结果

Search Results for " ns3 "

67

抑制剂 & 化合物

6

天然产物

61

重组蛋白

如果没找到您满意的产品或者您对产品有其他要求，可以联系我们专业顾问为您提供针对性的合理建议。 QQ咨询网站留言咨询

Cat. No.	Product Name	Target	Signaling Pathways
T39503	Hepatitis Virus C NS3 Protease Inhibitor 2
	Hepatitis Virus C NS3 Protease Inhibitor 2 is a peptide inhibitor derived from a product that targets the NS3 protease of the hepatitis C virus (HCV). Its inhibitory activity against the NS3 protease is characterized by a Ki value of 41 nM.
T62104	NS2B/NS3-IN-5
	NS2B/NS3-IN-5 (Compound 25b) 是一种变构的 DENV2 和 ZIKV NS2B/NS3 蛋白酶抑制剂，对 ZIKV 和 DENV2 的 NS2B/NS3 蛋白酶的IC50值分别为 0.67 μM 和 4.38 μM。
T60458	NS2B/NS3-IN-4
	NS2B/NS3-IN-4 (Compound 34e) 是一种变构的 DENV2和 ZIKVNS2B/NS3蛋白酶抑制剂，对 DENV2 和 ZIKV 的 NS2B/NS3蛋白酶的 IC50值分别为 0.69 µM 和 1.04 µM。
T62932	NS2B/NS3-IN-2
	NS2B/NS3-IN-2 是一种有效的、共价的登革病毒 (DENV)NS2B/NS3 抑制剂 (IC50: 6.0 nM，Ki: 0.66 μM)。NS2B/NS3-IN-2 可以明显提高细胞存活率，且没有细胞毒性。
T72887	NS2B/NS3-IN-7
	NS2B/NS3-IN-7 是一种高效的寨卡病毒 (Zika virus)NS2B-NS3 蛋白酶抑制剂，Ki 为 2.33 nM。NS2B/NS3-IN-7 能减少寨卡病毒感染的细胞数量。
T60881	NS2B/NS3-IN-3
	NS2B/NS3-IN-3 (Compd 66) 是Flavivirus NS2B-NS3蛋白酶的抑制剂。
T62437	NS2B/NS3-IN-6
	NS2B/NS3-IN-6 (Compound 1a) 是一种变构的 DENV 和 ZIKV NS2B/NS3 蛋白酶抑制剂，对 ZIKV 和 DENV 的 NS2B/NS3 蛋白酶的IC50值分别为 2.23 μM 和 25.2 μM。
T78653	NS2B/NS3-IN-3 hydrochloride	Virus Protease	Microbiology/Virology
	NS2B/NS3-IN-3 hydrochloride为Flavivirus NS2B-NS3蛋白酶的专一性抑制剂。
T22394	Paritaprevir ABT450,ABT-450,帕利普韦,Veruprevir	HCV Protease	Microbiology/Virology; Proteases/Proteasome
	Paritaprevir (ABT450) 是一种非结构蛋白 3/4A 蛋白酶抑制剂，对 HCV 1a 和 HCV 1b 的 EC50 值分别为 1 和 0.21 nM。它也是SARS-CoV 3CLpro 的抑制剂，IC50为 1.31 μM。
T33480	Montirelin NS 3,Montirelinum,CNK 602A,CNK-603
	Montirelin is an analog of thyrotropin-releasing hormone.
T16347	NS3623	Potassium Channel	Membrane transporter/Ion channel
	NS3623 是 hERG1 (KV11.1)钾通道激活剂，激活IKr 和Ito 电流，具有抗心律失常作用。NS3623也是 hERG1 通道抑制剂。
T22119	NS3694	Apoptosis	Apoptosis
	NS3694 是一种凋亡抑制剂，可抑制凋亡小体形成和半胱天冬酶活化。
T27613	inS3-54-A26	STAT	JAK/STAT signaling; Stem Cells
	inS3-54-A26 是 STAT3 的 DNA 结合域的抑制剂。 inS3-54-A26 抑制肿瘤生长、转移和 STAT3 的基因表达。
T4612	NS309	EGFR; Potassium Channel; HER	Angiogenesis; JAK/STAT signaling; Membrane transporter/Ion channel; Tyrosine Kinase/Adaptors
	NS309 是选择性钙依赖性钾离子通道 SK/IK 的激活剂，在 BK 通道上没有激活作用。
T15582	inS3-54A18	STAT	JAK/STAT signaling; Stem Cells
	inS3-54A18 是一种有效的 STAT3 抑制剂。 inS3-54A18 具有抗癌作用。
T9542	NS3861	AChR	Neuroscience
	NS3861 是烟碱型乙酰胆碱受体的激动剂，对α3β4 nAChR 具有高亲和力。能够分别与α3β4 (Ki:0.62 nM)、α3β2 (Ki:25 nM)、α4β4 (Ki:7.8 nM)、α4β2 (Ki:55 nM) 结合。
T81642	NS2B-NS3pro-IN-1	Virus Protease	Microbiology/Virology
	NS2B-NS3pro-IN-1为Zika Virus NS2B-NS3蛋白酶抑制剂，具有50 μM的EC50值，对Zika Virus (ZIKV)循环具有关键影响。
T81641	NS2B-NS3pro-IN-2	Virus Protease	Microbiology/Virology
	NS2B-NS3pro-IN-2是针对寨卡病毒NS2B-NS3蛋白酶的抑制剂，展示了在50μM浓度时的抗病毒特性。
T9450	NS3861 fumarate
	NS3861 fumarate 是烟碱型乙酰胆碱受体 (nAChRs) 的激动剂。NS3861 fumarate 是α3β4 nAChR 的部分激动剂。与α3β4、α3β2、α4β4、α4β2 的结合Ki 值分别为 0.62、25、7.8、55 nM。
T5938	4-Phenoxybenzylamine	HCV Protease	Microbiology/Virology; Proteases/Proteasome
	4-Phenoxybenzylamine 通过稳定无活性构象来抑制NS3蛋白的功能，对 HCV NS3/4a 的 IC50 约为 500 μM。
T4197	HZ-1157 HZ1157,DHFR-inhibitor	HCV Protease	Microbiology/Virology; Proteases/Proteasome
	HZ-1157 (DHFR-inhibitor) 是一种丙型肝炎病毒抑制剂，对 HCV NS3/4A 蛋白酶具有抑制活性。
T73097	SID-852843	Virus Protease	Microbiology/Virology
	SID-852843 是一种 WNV NS2B-NS3 蛋白酶抑制剂。SID-852843 可以抑制 WNV NS2B-NS3 蛋白酶活性 IC50 值为 0.105 μM。SID-852843 可用于病毒感染的研究。
T13397	ZINC03129319	Virus Protease	Microbiology/Virology
	ZINC03129319 是有效的登革病毒 NS2B-NS3蛋白酶抑制剂，抑制常数 Ki1和 Ki3分别为 92 μM 和 20 μM。
T6190	Telaprevir VX-950,LY-570310,Incivek,MP-424,特拉匹韦	HCV Protease; SARS-CoV	Microbiology/Virology; Proteases/Proteasome
	Telaprevir (Incivek) 是一种选择性可逆的HCV NS3-4A 蛋白酶抑制剂，作用于基因 1型 (H 株) NS3 蛋白酶结构域和 NS4A 辅因子肽，Ki 为 7 nM。它也是 SARS-CoV-2 3CLpro 抑制剂。
T5126	Glecaprevir ABT-493	HCV Protease; SARS-CoV	Microbiology/Virology; Proteases/Proteasome
	Glecaprevir (ABT-493) 是一种新型的 HCV NS3/4A 蛋白酶抑制剂，其 IC50值在 3.5 和 11.3 nM 之间。它也是 SARS-CoV 3CLpro 的抑制剂，IC50为 4.09 μM。
T4988	Boceprevir SCH 503034,EBP 520,波普瑞韦	HCV Protease; SARS-CoV	Microbiology/Virology; Proteases/Proteasome
	Boceprevir (SCH 503034) 是一种口服有效的选择性 HCV NS3 蛋白酶抑制剂。在酶试验中的 Ki 为 14 nM，在基于细胞的复制子试验中 EC90 为 350 nM。它也是 SARS-CoV-2 3CLpro 抑制剂。
T6025	Danoprevir R7227,丹诺普韦,ITMN-191,RG7227,RO5190591	HCV Protease; SARS-CoV	Microbiology/Virology; Proteases/Proteasome
	Danoprevir (RG7227) 是具有口服活性的NS3/4A 蛋白酶抑制剂，IC50值为 0.29 nM。它抑制 HCV 基因型 1a, 1b, 4, 5, 6 (IC50s=0.2-0.4 nM) 和 2b, 3a (IC50s=1.6, 3.5 nM)。它也是SARS-CoV 3CLpro 的抑制剂，IC50为 0.05 μM。
T19900	ARDP0006 1,8-二羟基-4,5-二硝基蒽醌	Others	Others
	ARDP0006 是 NS2B-NS3 蛋白酶的抑制剂。
T28830	Sovaprevir ACH 0141625,ACH0141625,ACH-0141625,ACH1625,ACH 1625,ACH-1625	HCV Protease	Microbiology/Virology; Proteases/Proteasome
	Sovaprevir 是一种非结构性3（NS3）蛋白酶抑制剂，有抗病毒活性，用于治疗 HCV 感染。
T4686	Simeprevir TMC435,西咪匹韦,TMC-435350,Olysio	HCV Protease; SARS-CoV	Microbiology/Virology; Proteases/Proteasome
	Simeprevir (TMC435) 是一种有效的 HCV NS3/4A 蛋白酶抑制剂，抑制 HCV 复制，EC50 为 7.8 nM。它也是 SARS-CoV-2 3CLpro 抑制剂。
T4474	Asunaprevir BMS-650032,阿那匹韦	HCV Protease; SARS-CoV	Microbiology/Virology; Proteases/Proteasome
	Asunaprevir (BMS-650032) 是一种有口服活性的 HCV NS3 蛋白酶抑制剂，IC50值为 0.2 nM-3.5 nM。它也是 SARS-CoV-2 3CLpro 抑制剂。
T3226	Paritaprevir ABT-450,Veruprevir,帕利瑞韦	HCV Protease	Microbiology/Virology; Proteases/Proteasome
	Paritaprevir (ABT-450) 是一种口服生物可利用的合成酰基磺酰胺抑制剂，可抑制丙型肝炎病毒 (HCV) 蛋白酶复合物，由非结构蛋白 3 和 4A (NS3/NS4A) 组成，对 HCV 基因型 1 具有潜在活性。给药后，paritaprevir 可逆地结合 HCV NS3/NS4A 蛋白酶的活性中心和结合位点，并阻止 NS3/NS4A 蛋白酶介导的多蛋白成熟。这会破坏病毒蛋白的加工和病毒复制复合物的形成，从而抑制病毒在 HCV 基因型 1 感染的宿主细胞中的复制。 NS3 是一种丝氨酸蛋白酶，对于 HCV 多蛋白内多个位点的蛋白水解切割至关重要，并且在 HCV 核糖核酸 (RNA) 复制过程中起关键作用。 NS4A 是 NS3 的激活因子。 HCV 是属于黄病毒科的一种小的、有包膜的单链 RNA 病毒，感染与肝细胞癌 (HCC) 的发展有关。
T4547	Grazoprevir MK-5172	HCV Protease; SARS-CoV	Microbiology/Virology; Proteases/Proteasome
	Grazoprevir (MK-5172) 是一种丙型肝炎病毒 NS3/4a 蛋白酶的选择性抑制剂，具有跨基因型和耐药变体的广泛活性，对 gt1b、gt1a、gt2a、gt2b 和 gt3a 的Ki 分别为 0.01 nM、0.01 nM、0.08 nM、0.15 nM 和 0.90 nM。它也是 SARS-CoV-2 3CLpro 抑制剂。
T19862	Voxilaprevir 维昔普维,伏西瑞韦	HCV Protease	Microbiology/Virology; Proteases/Proteasome
	Voxilaprevir 是丙型肝炎病毒非结构蛋白 3/4A 蛋白酶的抑制剂，具有抗病毒活性。它抑制基因型 1b 和 3a 野生型 NS3 蛋白酶的 Ki 值分别为 0.038 nM 和 0.066 nM。
T11540	HCV-IN-3	Others	Others
	HCV-IN-3 is a hepatitis C virus (HCV) NS3/4a protein inhibitor (IC50: 20 μM; Kd: 29 μM).
T16274	Narlaprevir SCH 900518,那拉匹韦	Others	Others
	Narlaprevir is an effective, selective, and orally bioavailable NS3 protease inhibitor(Ki=6 nM; EC90=40 nM).
T67707	Tyrphostin AG 538 AG 538	IGF-1R	Tyrosine Kinase/Adaptors
	Tyrphostin AG 538 是一种查尔酮化合物，是一种IGF-1受体激酶抑制剂（IC₅0 ：为400 nM），具有有效性、细胞渗透性、可逆性和竞争性。
T14555	BI-1230	HCV Protease	Microbiology/Virology; Proteases/Proteasome
	BI-1230 is a potent inhibitor of HCV NS3 protease, exhibiting efficacy in the low nanomolar range, and notably suppresses viral replication. This compound demonstrates high selectivity, distinguishing effectively between other serine/cysteine proteases. Additionally, BI-1230 exhibits favorable pharmacokinetic (PK) properties[1].
T68354	Danoprevir sodium
	Danoprevir sodium is an NS3/4A protease inhibitor used in the treatment of Hepatitis C
T70655	Furaprevir
	Furaprevir is an HCV NS3/4A Inhibitor
T30934	CID-50930756 CID 50930756,CID50930756
	CID-50930756 is a novel HCV NS3 helicase catalyzed ATP hydrolysis stimulator.
T26303	TYT-1 TYT 1,NSC298213,NSC-298213,NSC 298213
	TYT-1 is the most effective WNV NS3 inhibitor reported to date.
T37870	Bz-Nle-Lys-Arg-Arg-AMC
	Substrate for dengue virus NS2B-NS3 and yellow fever virus NS3 protease. The kcat/Km value of Bz-NleKRR-AMC for the dengue virus type 4 (DEN4) enzyme is > 800 fold higher than that of Boc-Gly-Arg-Arg-AMC, a widely used NS3 substrate (kcat = 2.9 s 1, Km = 8.6 μM for DEN4). For yellow fever virus NS3 protease the kcat value was 0.111 s 1, the Km value 14.6 μM.
T8675	Vaniprevir	Others	Others
	Vaniprevir is a macrocyclic hepatitis C virus NS3/4a protease inhibitor and is active against both the genotype 1 and genotype 2 NS3/4a protease enzymes. vaniprevir has good plasma exposure and excellent liver exposure in multiple species.
T69643	DGY-08-097
	DGY-08-097 is a novel HCV NS3 degrader, reducing susceptibility to resistance mutations, potently inhibiting HCV in a cellular infection model, exhibiting the most potent degradation (DC50 of 50nM at 4h) of HCV NS3.
T25171	BP13944 BP 13944,BP-13944
	BP13944 is used as a potential dengue virus NS2B/NS3 protease inhibitor.
T12065	Grazoprevir sodium salt MK-5172 (sodium salt)	Others	Others
	Grazoprevir sodium salt is a selective Hepatitis C virus NS3/4a protease inhibitor with broad activity across genotypes and resistant variants.
T71276	MK-2748
	MK-2748 is an inhibitor of NS3 protease, hepatitis C virus.
T71031	Deldeprevir Na
	Deldeprevir Na is an Antiviral Polyprotein cleavage inhibitor. HCV NS3/4A inhibitor.
T35043	Vedroprevir GS9451,GS 9451,GS-9451
	Vedroprevir, also known as GS9451, is a selective hepatitis C virus (HCV) NS3 protease inhibitor in the development of the treatment of genotype 1 (GT1) HCV infection.

化合物

Hepatitis Virus C NS3 Protease Inhibitor 2

Cat.No: T39503

Cat.No: T62104

Cat.No: T60458

Cat.No: T62932

Cat.No: T72887

Cat.No: T60881

Cat.No: T62437

NS2B/NS3-IN-3 hydrochloride

Cat.No: T78653

Target: Virus Protease

Cat.No: T22394

Synonym: ABT450,ABT-450,帕利普韦,Veruprevir

Target: HCV Protease

Cat.No: T33480

Synonym: NS 3,Montirelinum,CNK 602A,CNK-603

Cat.No: T16347

Target: Potassium Channel

Cat.No: T22119

Target: Apoptosis

Cat.No: T27613

Target: STAT

Cat.No: T4612

Target: EGFR, Potassium Channel, HER

Cat.No: T15582

Target: STAT

Cat.No: T9542

Target: AChR

NS2B-NS3pro-IN-1

Cat.No: T81642

Target: Virus Protease

NS2B-NS3pro-IN-2

Cat.No: T81641

Target: Virus Protease

NS3861 fumarate

Cat.No: T9450

4-Phenoxybenzylamine

Cat.No: T5938

Target: HCV Protease

Cat.No: T4197

Synonym: HZ1157,DHFR-inhibitor

Target: HCV Protease

Cat.No: T73097

Target: Virus Protease

Cat.No: T13397

Target: Virus Protease

Cat.No: T6190

Synonym: VX-950,LY-570310,Incivek,MP-424,特拉匹韦

Target: HCV Protease, SARS-CoV

Cat.No: T5126

Synonym: ABT-493

Target: HCV Protease, SARS-CoV

Cat.No: T4988

Synonym: SCH 503034,EBP 520,波普瑞韦

Target: HCV Protease, SARS-CoV

Cat.No: T6025

Synonym: R7227,丹诺普韦,ITMN-191,RG7227,RO5190591

Target: HCV Protease, SARS-CoV

Cat.No: T19900

Synonym: 1,8-二羟基-4,5-二硝基蒽醌

Target: Others

Cat.No: T28830

Synonym: ACH 0141625,ACH0141625,ACH-0141625,ACH1625,ACH 1625,ACH-1625

Target: HCV Protease

Cat.No: T4686

Synonym: TMC435,西咪匹韦,TMC-435350,Olysio

Target: HCV Protease, SARS-CoV

Cat.No: T4474

Synonym: BMS-650032,阿那匹韦

Target: HCV Protease, SARS-CoV

Cat.No: T3226

Synonym: ABT-450,Veruprevir,帕利瑞韦

Target: HCV Protease

Cat.No: T4547

Synonym: MK-5172

Target: HCV Protease, SARS-CoV

Cat.No: T19862

Synonym: 维昔普维,伏西瑞韦

Target: HCV Protease

Cat.No: T11540

Target: Others

Cat.No: T16274

Synonym: SCH 900518,那拉匹韦

Target: Others

Tyrphostin AG 538

Cat.No: T67707

Synonym: AG 538

Target: IGF-1R

Cat.No: T14555

Target: HCV Protease

Danoprevir sodium

Cat.No: T68354

Cat.No: T70655

Cat.No: T30934

Synonym: CID 50930756,CID50930756

Cat.No: T26303

Synonym: TYT 1,NSC298213,NSC-298213,NSC 298213

Bz-Nle-Lys-Arg-Arg-AMC

Cat.No: T37870

Cat.No: T8675

Target: Others

Cat.No: T69643

Cat.No: T25171

Synonym: BP 13944,BP-13944

Grazoprevir sodium salt

Cat.No: T12065

Synonym: MK-5172 (sodium salt)

Target: Others

Cat.No: T71276

Cat.No: T71031

Cat.No: T35043

Synonym: GS9451,GS 9451,GS-9451

Cat. No.	Product Name	Target	Signaling Pathways
T2718	Palmatine chloride	Others; Indoleamine 2,3-Dioxygenase (IDO); Aurora Kinase	Cell Cycle/Checkpoint; Chromatin/Epigenetic; Metabolism; Others
	Palmatine chloride 是口服具有活力的不可逆 IDO-1抑制剂。它能够减轻结肠损伤，预防肠道菌群失调和调节色氨酸分解代谢，并改善 DSS 诱发的结肠炎。
T5S0802	Palmatine 巴马汀,Berbericinine,Burasaine	Indoleamine 2,3-Dioxygenase (IDO); AChR; AChE; Aurora Kinase	Cell Cycle/Checkpoint; Chromatin/Epigenetic; Metabolism; Neuroscience
	Palmatine (Burasaine) 是口服具有活力的、不可逆IDO-1抑制剂。它可以减轻结肠损伤，预防肠道菌群失调和调节色氨酸分解代谢，从而改善DSS (Dextran Sulphate Sodium Salt) 诱发的结肠炎。它有用于结肠炎的研究潜力。
T5429	Theaflavin 3,3'-digallate 茶黄素-3,3'-双没食子酸,8-Gingerol,TFDG	Virus Protease; Antioxidant; HIV Protease; HSV	Microbiology/Virology; oxidation-reduction; Proteases/Proteasome
	Theaflavin 3,3'-digallate (8-Gingerol) 是一种寨卡病毒蛋白酶抑制剂，IC50为 2.3 μM。它直接与 ZIKVpro 结合并抑制 ZIKV 复制，可抑制 gp41 和 NS2B-3 蛋白酶的活性，并具有抗 HSV 和 HIV-1病毒活性。它是红茶中的主要多酚，有抗肿瘤作用。
T23664	Agathisflavone 6,8'-Biapigenin
	Agathisflavone is a NS2B-NS3 proteases inhibitor of the Dengue virus serotypes 2 and 3.
TN1033	Sennidin A	HCV Protease; transporter; Akt; PI3K	Cytoskeletal Signaling; Metabolism; Microbiology/Virology; PI3K/Akt/mTOR signaling; Proteases/Proteasome
	Sennidin A 是从狭叶番泻分离得到的一种天然产物，能够抑制 HCV NS3 解旋酶，其 IC50值为0.8 μM。它诱导 Akt 和葡萄糖转运蛋白4的磷酸化，刺激葡萄糖掺入。
T72508	Palmatine hydroxide
	Palmatine hydroxide 是不可逆的口服活性IDO-1抑制剂，其对HEK 293-hIDO-1 和 rhIDO-1的IC50值分别为3 μM和157 μM。该化合物还能非竞争性抑制(WNV)NS2B-NS3蛋白酶，IC50值为96 μM。Palmatine hydroxide展现了抗癌、抗炎、神经保护、抗细菌和抗病毒的活性。

天然产物

Palmatine chloride

Cat.No: T2718

Target: Others, Indoleamine 2,3-Dioxygenase (IDO), Aurora Kinase

Cat.No: T5S0802

Synonym: 巴马汀,Berbericinine,Burasaine

Target: Indoleamine 2,3-Dioxygenase (IDO), AChR, AChE, Aurora Kinase

Theaflavin 3,3'-digallate

Cat.No: T5429

Synonym: 茶黄素-3,3'-双没食子酸,8-Gingerol,TFDG

Target: Virus Protease, Antioxidant, HIV Protease, HSV

Cat.No: T23664

Synonym: 6,8'-Biapigenin

Cat.No: TN1033

Target: HCV Protease, transporter, Akt, PI3K

Palmatine hydroxide

Cat.No: T72508

Species：

Expression System：

Tag：

Cat. No.	Product Name	Species	Expression System
TMPY-00323	Hepatitis C virus (HCV-1a) NS3 protease/helicase immunodominant region Protein (aa 1356-1459, GST) NS3	HCV	E. coli
	HCV NS3 displays three enzymatic activities: serine protease, NTPase, and RNA helicase. HCV NS3 serine protease, in association with NS4A, is responsible for the cleavages of NS3-NS4A, NS4A-NS4B, NS4B-NS5A, and NS5A-NS5B. HCV NS3 RNA helicase binds to RNA and unwinds dsRNA in the 3' to 5' direction, and likely RNA stable secondary structure in the template strand (By similarity). Cleaves and inhibits the host antiviral protein MAVS. NS3/NS4A complex also prevents phosphorylation of human IRF3, t...
TMPY-01888	KRAS Protein,Human, Recombinant (Q61H, His) KRAS2,C-K-RAS,Kirsten rat sarcoma viral oncogene homolog,K-R...	Human	E. coli
	KRAS Protein,Human, Recombinant (Q61H, His) is expressed in E. coli expression system with His tag. The predicted molecular weight is 22.5 kDa and the accession number is P01116-2.
TMPY-04116	KRAS Protein,Human,Recombinant(G12C & Q61H, His) NS,CFC2,K-RAS4B,C-K-RAS,KRAS2,K-RAS2B,K-RAS,Kirsten...	Human	E. coli
	KRAS Protein,Human,Recombinant(G12C & Q61H, His) is expressed in E. coli expression system with His tag. The predicted molecular weight is 23.3 kDa and the accession number is P01116-2.
TMPY-06056	KRAS Protein, Human, Recombinant (G12D, His) KRAS1,K-RAS4B,Kirsten rat sarcoma viral oncogene homolog,RAL...	Human	E. coli
	KRAS Protein, Human, Recombinant (G12D, His) is expressed in E. coli expression system with His tag. The predicted molecular weight is 22 kDa and the accession number is P01116-2.
TMPY-04113	KRAS Protein,Human,Recombinant(G12D & Q61H, His) Kirsten rat sarcoma viral oncogene homolog,KRAS2,KI-RAS,RASK...	Human	E. coli
	KRAS Protein,Human,Recombinant(G12D & Q61H, His) is expressed in E. coli expression system with His tag. The predicted molecular weight is 23.3 kDa and the accession number is P01116-2.
TMPK-01428	HLA-A*11:01&B2M&KRAS G12D (VVGADGVGK) Monomer Protein, Human, MHC (His & Avi) CFC2,K-RAS4B,K-Ras 2,C-K-RAS,RASK2,NS3,RAL...	Human	E. coli
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01405	HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi) KI-RAS,RASK2,K-Ras 2,MHC,KRAS,KRAS1,NS3,K-...	Human	E. coli
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01443	HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (His & Avi), FITC-Labeled KRAS1,C-K-RAS,K-RAS4B,RALD,K-Ras 2,K-RAS2A,K-RAS2B,KRAS2,	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01450	HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi), Biotinylated KRAS1,MHC,K-RAS4B,KRAS,CFC2,K-RAS2B,K-Ras 2,C-K-RAS,RASK2,K-...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01462	HLA-A*11:01&B2M&KRAS G12C (VVVGACGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated K-RAS4A,K-RAS2A,CFC2,KRAS1,K-RAS4B,C-K-RAS,KRAS,K-RAS2B,K-Ra...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01511	HLA-A*03:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated GTPase Kras,K-RAS4A,KI-RAS,K-RAS4B,C-K-RAS,K-Ras 2,RASK2,K-R...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
TMPK-01460	HLA-A*11:01&B2M&KRAS G12S (VVVGASGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated MHC,K-RAS2A,KI-RAS,K-RAS4B,RALD,NS3,GTPase...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01427	HLA-A*11:01&B2M&KRAS G12D (VVGADGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated C-K-RAS,K-RAS4B,GTPase Kras,K-RAS4A,K-RAS2A,KRAS2,CFC2,RASK2...	Human	E. coli
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01403	HLA-A11:01&B2M&KRAS G12V (VVGAVGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi) K-Ras 2,KI-RAS,CFC2,KRAS1,GTPase Kras,KRAS,K-RAS4B,RALD,...*	Human	E. coli
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01399	HLA-A*11:01&B2M&KRAS WT (VVGAGGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated K-RAS2A,NS3,KRAS2,CFC2,K-RAS4B,GTPase Kras...	Human	E. coli
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
TMPK-01404	HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi), Biotinylated NS,KRAS,KRAS1,KRAS2,MHC,RALD,K-RAS4A,K-RAS2A,K-RAS4...	Human	E. coli
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01479	HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated NS3,KRAS1,K-Ras 2,K-RAS2A,K-RAS2B,C-K-RAS,...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
TMPK-01525	HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated CFC2,RALD,K-Ras 2,MHC,C-K-RAS,NS3,GTPase K...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01461	HLA-A*11:01&B2M&KRAS G12S (VVVGASGVGK) Monomer Protein, Human, MHC (His & Avi) C-K-RAS,KRAS,RASK2,K-Ras 2,K-RAS2A,MHC,CFC2,K-RAS4B,K-RAS2B,...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01434	HLA-A*11:01&B2M&KRAS G12R (VVVGARGVGK) Tetramer Protein, Human, MHC (His & Avi) RASK2,CFC2,GTPase Kras,KRAS,K-RAS2B,MHC,K-RAS2A,K-RAS4A,KRAS...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPY-06345	KRAS Protein, Human, Recombinant (His & Avi), Biotinylated RASK2,K-RAS2A,RALD,C-K-RAS,NS3,Kirsten rat...	Human	E. coli
	KRAS Protein, Human, Recombinant (His & Avi), Biotinylated is expressed in E. coli expression system with His and Avi tag. The predicted molecular weight is 23.78 kDa and the accession number is P01116-2.
TMPK-01408	HLA-A*02:01&B2M&KRAS G12V (KLVVVGAVGV) Monomer Protein, Human, MHC (His & Avi), Biotinylated RALD,KRAS1,KRAS2,K-RAS2B,CFC2,NS3,GTPase K...	Human	E. coli
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01401	HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi) MHC,CFC2,K-Ras 2,RALD,K-RAS4A,NS,RASK2,GTPase Kras,...	Human	E. coli
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
TMPK-01429	HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi), Biotinylated MHC,K-Ras 2,NS,K-RAS4A,KRAS,NS3,K...	Human	E. coli
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01488	HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (His & Avi) K-RAS4A,MHC,GTPase Kras,K-Ras 2,KRAS2,K-RAS2B,CFC2,RASK2,RAL...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
TMPK-01451	HLA-C 03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi) NS3,K-RAS4A,K-Ras 2,NS,KRAS1,RASK...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01529	HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer Protein, Human, MHC (His & Avi) K-RAS4A,KRAS1,MHC,K-RAS2B,CFC2,GTPase Kras,K-RAS4B,KRAS2,	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01458	HLA-A*11:01&B2M&KRAS G12A (VVVGAAGVGK) Monomer Protein, Human, MHC (His & Avi) K-Ras 2,GTPase Kras,KRAS2,MHC,K-RAS4A,CFC2,K-RAS2A,KRAS1,RAS...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01463	HLA-A*11:01&B2M&KRAS G12C (VVVGACGVGK) Monomer Protein, Human, MHC (His & Avi) C-K-RAS,KI-RAS,KRAS1,K-RAS4A,KRAS2,CFC2,MHC,NS3...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01518	HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer Protein, Human, MHC (His & Avi) MHC,NS,KRAS1,K-RAS2A,GTPase Kras,KRAS,RALD,KRAS2,RA...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01527	HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (His & Avi) NS,RALD,C-K-RAS,RASK2,K-RAS2B,KRAS2,KRAS,K-RAS2A,K-...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01510	HLA-A*03:01&B2M&KRAS WT (VVVGAGGVGK) Tetramer Protein, Human, MHC (His & Avi) NS,NS3,KRAS2,RASK2,MHC,RALD,K-Ras...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
TMPK-01433	HLA-A*11:01&B2M&KRAS G12C (VVVGACGVGK) Tetramer Protein, Human, MHC (His & Avi) GTPase Kras,NS3,K-Ras 2,K-RAS2B,RALD,MHC,R...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPY-06138	KRAS Protein, Human, Recombinant (61Q, His) Kirsten rat sarcoma viral oncogene homolog,K-RAS2B,NS	Human	E. coli
	KRAS Protein, Human, Recombinant (61Q, His) is expressed in E. coli expression system with His tag. The predicted molecular weight is 21.9 kDa and the accession number is P01116-2.
TMPK-01402	HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi), Biotinylated KRAS1,NS,CFC2,K-RAS4B,RASK2,K-Ras 2,KI-RAS,GTPase K...	Human	E. coli
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01430	HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi) K-RAS2A,RALD,NS3,K-Ras 2,KI-RAS,NS	Human	E. coli
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01432	HLA-A*11:01&B2M&KRAS G12A (VVVGAAGVGK) Tetramer Protein, Human, MHC (His & Avi) RASK2,K-RAS4A,K-RAS4B,KRAS2,CFC2,MHC,KRAS,KI-RAS,K-RAS2B,C-K...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01440	HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer Protein, Human, MHC (His & Avi), PE-Labeled RASK2,KI-RAS,C-K-RAS,KRAS,MHC,NS,K-RAS4A,K-RAS2B,CF...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01528	HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (His & Avi) KRAS1,MHC,K-RAS2B,K-RAS4B,NS,GTPase Kras,K-Ras 2,KI...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01456	HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Tetramer Protein, Human, MHC (His & Avi) KRAS2,NS,MHC,C-K-RAS,KRAS1,K-RAS2A,K-RAS2B,KI-RAS,K...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01512	HLA-A*03:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (His & Avi) K-Ras 2,NS,NS3,K-RAS2B,CFC2,MHC,K...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
TMPK-01465	HLA-A*11:01&B2M&KRAS G12R (VVVGARGVGK) Monomer Protein, Human, MHC (His & Avi) NS3,K-RAS2A,CFC2,KRAS,GTPase Kras,K-RAS2B,...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01435	HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer Protein, Human, MHC (His & Avi), PE-Labeled KRAS2,NS3,RASK2,KI-RAS,RALD,K-RAS2B,K-RAS4...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01438	HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Tetramer Protein, Human, MHC (His & Avi), PE-Labeled RASK2,KRAS2,KRAS1,MHC,C-K-RAS,KI-RAS,K-RAS4B,RALD,K-RAS4A,	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
TMPK-01507	HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Tetramer Protein, Human, MHC (His & Avi) K-RAS2A,K-RAS4B,KI-RAS,RALD,C-K-RAS,RASK2,NS,MHC,	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01400	HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi), Biotinylated NS,KRAS1,RALD,K-RAS2A,K-RAS2B,K-RAS4A,MHC,RASK2,KRA...	Human	E. coli
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
TMPK-01407	HLA-A*02:01&B2M&KRAS WT (KLVVVGAGGV) Monomer Protein, Human, MHC (His & Avi), Biotinylated KRAS2,RALD,C-K-RAS,NS3,MHC,CFC2,KRAS,KI-RA...	Human	E. coli
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
TMPK-01536	HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated NS3,MHC,KRAS,RALD,CFC2,K-RAS2B,GTPase Kras...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01464	HLA-A*11:01&B2M&KRAS G12R (VVVGARGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated C-K-RAS,K-RAS4A,GTPase Kras,K-RAS2A,NS,K-RAS2B,MHC,...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01489	HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Tetramer Protein, Human, MHC (His & Avi) K-RAS2A,NS3,KRAS1,KRAS2,MHC,NS,K-...	Human	HEK293 Cells
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
------------------------ 更多 ------------------------

重组蛋白

Hepatitis C virus (HCV-1a) NS3 protease/helicase immunodominant region Protein (aa 1356-1459, GST)

Cat.No: TMPY-00323

Species: HCV

Expression System: E. coli

KRAS Protein,Human, Recombinant (Q61H, His)

Cat.No: TMPY-01888

Species: Human

Expression System: E. coli

KRAS Protein,Human,Recombinant(G12C & Q61H, His)

Cat.No: TMPY-04116

Species: Human

Expression System: E. coli

KRAS Protein, Human, Recombinant (G12D, His)

Cat.No: TMPY-06056

Species: Human

Expression System: E. coli

KRAS Protein,Human,Recombinant(G12D & Q61H, His)

Cat.No: TMPY-04113

Species: Human

Expression System: E. coli

HLA-A*11:01&B2M&KRAS G12D (VVGADGVGK) Monomer Protein, Human, MHC (His & Avi)

Cat.No: TMPK-01428

Species: Human

Expression System: E. coli

HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi)

Cat.No: TMPK-01405

Species: Human

Expression System: E. coli

HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (His & Avi), FITC-Labeled

Cat.No: TMPK-01443

Species: Human

Expression System: HEK293 Cells

HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi), Biotinylated

Cat.No: TMPK-01450

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS G12C (VVVGACGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated

Cat.No: TMPK-01462

Species: Human

Expression System: HEK293 Cells

HLA-A*03:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated

Cat.No: TMPK-01511

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS G12S (VVVGASGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated

Cat.No: TMPK-01460

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS G12D (VVGADGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated

Cat.No: TMPK-01427

Species: Human

Expression System: E. coli

HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi)

Cat.No: TMPK-01403

Species: Human

Expression System: E. coli

HLA-A*11:01&B2M&KRAS WT (VVGAGGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated

Cat.No: TMPK-01399

Species: Human

Expression System: E. coli

HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi), Biotinylated

Cat.No: TMPK-01404

Species: Human

Expression System: E. coli

HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated

Cat.No: TMPK-01479

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated

Cat.No: TMPK-01525

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS G12S (VVVGASGVGK) Monomer Protein, Human, MHC (His & Avi)

Cat.No: TMPK-01461

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS G12R (VVVGARGVGK) Tetramer Protein, Human, MHC (His & Avi)

Cat.No: TMPK-01434

Species: Human

Expression System: HEK293 Cells

KRAS Protein, Human, Recombinant (His & Avi), Biotinylated

Cat.No: TMPY-06345

Species: Human

Expression System: E. coli

HLA-A*02:01&B2M&KRAS G12V (KLVVVGAVGV) Monomer Protein, Human, MHC (His & Avi), Biotinylated

Cat.No: TMPK-01408

Species: Human

Expression System: E. coli

HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi)

Cat.No: TMPK-01401

Species: Human

Expression System: E. coli

HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi), Biotinylated

Cat.No: TMPK-01429

Species: Human

Expression System: E. coli

HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (His & Avi)

Cat.No: TMPK-01488

Species: Human

Expression System: HEK293 Cells

HLA-C 03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi)

Cat.No: TMPK-01451

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer Protein, Human, MHC (His & Avi)

Cat.No: TMPK-01529

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS G12A (VVVGAAGVGK) Monomer Protein, Human, MHC (His & Avi)

Cat.No: TMPK-01458

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS G12C (VVVGACGVGK) Monomer Protein, Human, MHC (His & Avi)

Cat.No: TMPK-01463

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer Protein, Human, MHC (His & Avi)

Cat.No: TMPK-01518

Species: Human

Expression System: HEK293 Cells

HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (His & Avi)

Cat.No: TMPK-01527

Species: Human

Expression System: HEK293 Cells

HLA-A*03:01&B2M&KRAS WT (VVVGAGGVGK) Tetramer Protein, Human, MHC (His & Avi)

Cat.No: TMPK-01510

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS G12C (VVVGACGVGK) Tetramer Protein, Human, MHC (His & Avi)

Cat.No: TMPK-01433

Species: Human

Expression System: HEK293 Cells

KRAS Protein, Human, Recombinant (61Q, His)

Cat.No: TMPY-06138

Species: Human

Expression System: E. coli

HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi), Biotinylated

Cat.No: TMPK-01402

Species: Human

Expression System: E. coli

HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi)

Cat.No: TMPK-01430

Species: Human

Expression System: E. coli

HLA-A*11:01&B2M&KRAS G12A (VVVGAAGVGK) Tetramer Protein, Human, MHC (His & Avi)

Cat.No: TMPK-01432

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer Protein, Human, MHC (His & Avi), PE-Labeled

Cat.No: TMPK-01440

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (His & Avi)

Cat.No: TMPK-01528

Species: Human

Expression System: HEK293 Cells

HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Tetramer Protein, Human, MHC (His & Avi)

Cat.No: TMPK-01456

Species: Human

Expression System: HEK293 Cells

HLA-A*03:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (His & Avi)

Cat.No: TMPK-01512

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS G12R (VVVGARGVGK) Monomer Protein, Human, MHC (His & Avi)

Cat.No: TMPK-01465

Species: Human

Expression System: HEK293 Cells

HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer Protein, Human, MHC (His & Avi), PE-Labeled

Cat.No: TMPK-01435

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Tetramer Protein, Human, MHC (His & Avi), PE-Labeled

Cat.No: TMPK-01438

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Tetramer Protein, Human, MHC (His & Avi)

Cat.No: TMPK-01507

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi), Biotinylated

Cat.No: TMPK-01400

Species: Human

Expression System: E. coli

HLA-A*02:01&B2M&KRAS WT (KLVVVGAGGV) Monomer Protein, Human, MHC (His & Avi), Biotinylated

Cat.No: TMPK-01407

Species: Human

Expression System: E. coli

HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated

Cat.No: TMPK-01536

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS G12R (VVVGARGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated

Cat.No: TMPK-01464

Species: Human

Expression System: HEK293 Cells

HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Tetramer Protein, Human, MHC (His & Avi)

Cat.No: TMPK-01489

Species: Human

Expression System: HEK293 Cells

--------- 更多 ---------

我们的所有产品和服务仅用于科学研究，不能被用于人体，我们也不向个人提供产品和服务。

Copyright © 2015-2024 TargetMol Chemicals Inc. All rights reserved. 沪ICP备20019793号-4

沪公网安备 31010602006700号

沪公网安备 31010602006700号

TargetMol Loading

联系我们

电话：

400-820-0310

邮箱：

service@tsbiochem.com

QQ：

2881945090（终端用户）

2885109491（经销商）

经销：

终端：

地址：

上海市静安区江场三路238号8楼